ConductScience.org, home

Paper8324869

Disposition of total and unbound etoposide following high-dose therapy.

Schwinghammer TL and 6 others. Cancer Chemother Pharmacol, 1993. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Disposition of total and unbound etoposide following high-dose therapy. Papers, record 8324869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8324869

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Disposition of total and unbound etoposide following high-dose therapy.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1993
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.98
iCite
Revised in PubMed
2019-08-30
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schwinghammer TLT L
2Fleming RAR A
3Rosenfeld CSC S
4Przepiorka DD
5Shadduck RKR K
6Bloom EJE J
7Stewart CFC F

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone Marrow TransplantationMajor topic
EtoposideMajor topic
Adolescent
Adult
Female
Half-Life
Humans
Male
Middle Aged
Protein Binding
Regression Analysis
Serum Albumin

Source PubMed

Download CSV of topics

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16644611Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis.J Pharm Sci1983https://conductscience.org/library/papers/6644611PubMed
21732431Increased teniposide clearance with concomitant anticonvulsant therapy.J Clin Oncol1992https://conductscience.org/library/papers/1732431PubMed
31640365Factors affecting in vitro protein binding of etoposide in humans.J Pharm Sci1992https://conductscience.org/library/papers/1640365PubMed
42026183Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.Exp Hematol1991https://conductscience.org/library/papers/2026183PubMed
56574831Busulfan kinetics.Clin Pharmacol Ther1983https://conductscience.org/library/papers/6574831PubMed
66330904The role of autologous bone marrow transplantation in various malignancies.Semin Hematol1984https://conductscience.org/library/papers/6330904PubMed
72596777Busulphan and phenytoin.Ann Intern Med1989https://conductscience.org/library/papers/2596777PubMed
83643849Pharmacokinetics of high dose etoposide (VP 16-213).Eur J Cancer Clin Oncol1986https://conductscience.org/library/papers/3643849PubMed
92230875Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.J Clin Oncol1990https://conductscience.org/library/papers/2230875PubMed
106151067Convulsions due to high-dose busulphan.Lancet1984https://conductscience.org/library/papers/6151067PubMed
116690051Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.Cancer Res1984https://conductscience.org/library/papers/6690051PubMed
123598607Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.J Clin Oncol1987https://conductscience.org/library/papers/3598607PubMed
133548841Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.Blood1987https://conductscience.org/library/papers/3548841PubMed
142178849Pharmacokinetic drug interactions with phenytoin (Part I).Clin Pharmacokinet1990https://conductscience.org/library/papers/2178849PubMed
152910637Altered protein binding of etoposide in patients with cancer.Clin Pharmacol Ther1989https://conductscience.org/library/papers/2910637PubMed
161914374Relation of systemic exposure to unbound etoposide and hematologic toxicity.Clin Pharmacol Ther1991https://conductscience.org/library/papers/1914374PubMed
174063137The effect of etoposide on human CFU-GM.Br J Cancer1985https://conductscience.org/library/papers/4063137PubMed
183284691Pharmacokinetics of high-dose etoposide.Clin Pharmacol Ther1988https://conductscience.org/library/papers/3284691PubMed
196707876High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection.J Pharm Sci1984https://conductscience.org/library/papers/6707876PubMed
203772420Etoposide pharmacokinetics in patients with normal and abnormal organ function.J Clin Oncol1986https://conductscience.org/library/papers/3772420PubMed

See all 21 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
27504190
Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation.
J Pharm Health Care Sci2016https://conductscience.org/library/papers/27504190PubMed
26040247
Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse.
Arch Immunol Ther Exp (Warsz)2015https://conductscience.org/library/papers/26040247PubMed
16524321Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.Drug Saf2006https://conductscience.org/library/papers/16524321PubMed
15139794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
8070032Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070032PubMed
7554043Etoposide protein binding in cancer patients.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554043PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8324869

GET https://conductscience.org/api/papers/v1/8324869/references?page=2